XBiotech Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the three and nine months ended September 30, 2026.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $105,037 thousand as of September 30, 2026, down from $125,551 thousand at December 31, 2025.
  • Total assets: Total assets were $128,611 thousand at September 30, 2026, compared with $150,082 thousand at December 31, 2025.
  • Accumulated deficit: The accumulated deficit increased to $153,070 thousand from $136,377 thousand at December 31, 2025.
  • Total liabilities: Total liabilities decreased to $4,546 thousand from $9,732 thousand at December 31, 2025.
  • Shares outstanding: 30,487,731 common shares were issued and outstanding as of both September 30, 2026 and December 31, 2025, with no change during the period.
  • Common stock balance: The common stock balance was $277,135 thousand at September 30, 2026, up from $276,727 thousand at December 31, 2025.

XBiotech's Financial Position for the Quarter Ended September 30, 2026

According to the filing, XBiotech Inc. (NASDAQ:XBIT), a British Columbia, Canada-incorporated company headquartered in Austin, Texas, reported total assets of $128,611 thousand as of September 30, 2026. The company's current assets of $106,356 thousand were composed primarily of cash and cash equivalents of $105,037 thousand, alongside accrued interest receivable of $265 thousand and prepaid expenses and other current assets of $1,054 thousand. Property and equipment, net, was reported at $22,255 thousand.

The filing disclosed that total current liabilities fell to $2,692 thousand from $7,929 thousand at December 31, 2025, with accounts payable declining to $581 thousand and accrued expenses falling to $2,107 thousand. Long-term liabilities totaled $1,854 thousand, consisting of long-term income tax payable of $1,849 thousand and a deferred tax liability of $5 thousand. The company reported no shares of preferred stock outstanding, and common stock remained unchanged at 30,487,731 shares for both period-end dates reported.

The accumulated deficit grew to $153,070 thousand from $136,377 thousand at December 31, 2025, reflecting an increase of $16,693 thousand over the nine-month period. The filing notes that forward-looking statements contained within are "subject to inherent risks and uncertainties" and are the company's own characterizations, subject to its stated cautionary language.

What Was Disclosed

XBiotech filed its Form 10-Q for the quarter ended September 30, 2026, disclosing condensed consolidated balance sheet data showing a cash balance of $105,037 thousand, total assets of $128,611 thousand, reduced total liabilities of $4,546 thousand, and an accumulated deficit of $153,070 thousand.